Latest Insider Transactions at Catalyst Pharmaceuticals, Inc. (CPRX)
This section provides a real-time view of insider transactions for Catalyst Pharmaceuticals, Inc. (CPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CATALYST PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CATALYST PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,353
-1.23%
|
-
|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,667
+4.82%
|
-
|
|
Feb 14
2025
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.54%
|
-
|
|
Feb 14
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,965
-11.7%
|
-
|
|
Feb 14
2025
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+24.64%
|
-
|
|
Feb 14
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,125
-9.32%
|
-
|
|
Feb 14
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,667
+24.13%
|
-
|
|
Feb 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,435
-3.41%
|
-
|
|
Feb 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.3%
|
-
|
|
Feb 14
2025
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+37.22%
|
-
|
|
Feb 14
2025
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,667
+1.42%
|
-
|
|
Feb 14
2025
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.8%
|
-
|
|
Feb 14
2025
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.11%
|
-
|
|
Feb 14
2025
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,574
-0.58%
|
-
|
|
Feb 14
2025
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.45%
|
-
|
|
Jan 08
2025
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+9.24%
|
$100,000
$2.24 P/Share
|
|
Jan 02
2025
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,600
-3.81%
|
-
|
|
Jan 02
2025
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,105
+13.16%
|
-
|
|
Jan 02
2025
|
Michael Wayne Kalb Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,941
-41.2%
|
-
|
|
Jan 02
2025
|
Michael Wayne Kalb Executive Vice President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,138
+50.0%
|
-
|
|
Dec 27
2024
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+32.68%
|
-
|
|
Dec 27
2024
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,345
-6.4%
|
-
|
|
Dec 27
2024
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+15.39%
|
-
|
|
Dec 27
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,839
-14.37%
|
-
|
|
Dec 27
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,667
+24.49%
|
-
|
|
Dec 27
2024
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.3%
|
-
|
|
Dec 27
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,941
-1.06%
|
-
|
|
Dec 27
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+3.51%
|
-
|
|
Dec 27
2024
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
324
-0.14%
|
-
|
|
Dec 27
2024
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.56%
|
-
|
|
Dec 27
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,541
-5.46%
|
-
|
|
Dec 27
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+12.19%
|
-
|
|
Dec 27
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.38%
|
-
|
|
Dec 27
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.18%
|
-
|
|
Dec 27
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+1.47%
|
-
|
|
Dec 13
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
235,000
+20.31%
|
$940,000
$4.01 P/Share
|
|
Dec 10
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.21%
|
$160,000
$4.01 P/Share
|
|
Dec 10
2024
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-6.78%
|
$1,050,000
$21.93 P/Share
|
|
Dec 10
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.35%
|
$200,000
$4.01 P/Share
|
|
Dec 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,355
-11.54%
|
-
|
|
Dec 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,039
+28.26%
|
-
|
|
Dec 09
2024
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,415
-7.45%
|
-
|
|
Dec 09
2024
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,855
+17.46%
|
-
|
|
Dec 09
2024
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.32%
|
-
|
|
Dec 09
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.21%
|
-
|
|
Dec 09
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,533
+0.08%
|
-
|
|
Dec 09
2024
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+50.0%
|
-
|
|
Dec 09
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,720
-0.97%
|
-
|
|
Dec 09
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,067
+3.81%
|
-
|
|
Dec 09
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.4%
|
-
|